Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2350
+0.0048 (2.09%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Theriva Biologics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-12.07-15.02-18.73-22.09-19.29-14.27
Net Income
-13.13-25.25-25.65-18.35-20.03-23.19
Earnings Per Share
-0.42-2.08-19.03-28.48-32.66-47.57
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
11.3413.0611.6123.1841.7967.33
Total Debt
3.552.631.572.151.681.53
Net Cash (Debt)
7.7810.4310.0421.0240.1165.8
Net Cash Growth
-15.66%3.81%-52.22%-47.58%-39.05%1043.52%
Net Cash Per Share
0.250.867.4532.6365.41134.97

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-12.74-16.67-16.94-19-19.08-12.89
Capital Expenditures
-0.02-0.04-0-0.2-0.12-0.01
Free Cash Flow
-12.76-16.7-16.94-19.2-19.2-12.9
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.